Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

333
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
333
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teledermatology: The perspective of French general practitioners.

Annales de dermatologie et de venereologie·2021
Same author

Which patients present to dermatologic emergencies? A survey on 1561 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation.

The British journal of dermatology·2019
Same author

Corrigendum: Adaptive biomedical innovation: Evolving our global system to sustainably and safely bring new medicines to patients in need.

Clinical pharmacology and therapeutics·2017
Same author

[Proliferating trichilemmal cyst: An unusual presentation].

Annales de dermatologie et de venereologie·2017
Same author

Accuracy of injection and short-term pain relief following intra-articular corticosteroid injection in knee osteoarthritis - an observational study.

BMC musculoskeletal disorders·2017
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Bridging the Bio-Electronic Interface with Biofabrication
16:38

Bridging the Bio-Electronic Interface with Biofabrication

Published on: June 6, 2012

17.4K

Adaptive Biomedical Innovation.

P K Honig1, G Hirsch2

  • 1Collegeville, Pennsylvania, USA.

Clinical Pharmacology and Therapeutics
|November 19, 2016
PubMed
Summary
This summary is machine-generated.

Adaptive Biomedical Innovation (ABI) offers a collaborative framework to speed up new medicine delivery. This multistakeholder approach enhances patient access and creates a sustainable ecosystem for medical advancements.

More Related Videos

BioMEMS: Forging New Collaborations Between Biologists and Engineers
07:26

BioMEMS: Forging New Collaborations Between Biologists and Engineers

Published on: November 1, 2007

8.7K
Bioelectric Analyses of an Osseointegrated Intelligent Implant Design System for Amputees
14:31

Bioelectric Analyses of an Osseointegrated Intelligent Implant Design System for Amputees

Published on: July 15, 2009

14.6K

Related Experiment Videos

Last Updated: Mar 11, 2026

Bridging the Bio-Electronic Interface with Biofabrication
16:38

Bridging the Bio-Electronic Interface with Biofabrication

Published on: June 6, 2012

17.4K
BioMEMS: Forging New Collaborations Between Biologists and Engineers
07:26

BioMEMS: Forging New Collaborations Between Biologists and Engineers

Published on: November 1, 2007

8.7K
Bioelectric Analyses of an Osseointegrated Intelligent Implant Design System for Amputees
14:31

Bioelectric Analyses of an Osseointegrated Intelligent Implant Design System for Amputees

Published on: July 15, 2009

14.6K

Area of Science:

  • Biomedical innovation
  • Health economics
  • Translational science

Background:

  • Current innovation models face fragmentation and linearity, delaying clinical value delivery.
  • A need exists for a cohesive strategy to optimize new medicine development and patient access.
  • The existing ecosystem requires enhancement for greater sustainability and efficiency.

Discussion:

  • Adaptive Biomedical Innovation (ABI) proposes a multistakeholder framework to address systemic inefficiencies.
  • ABI aims to streamline decision-making processes, fostering collaboration across diverse entities.
  • This approach seeks to accelerate the translation of research into tangible patient benefits.

Key Insights:

  • ABI facilitates a paradigm shift from linear to collaborative innovation.
  • It optimizes the benefit and accessibility of novel therapeutics for patients.
  • The framework promotes a more sustainable and robust innovation ecosystem.

Outlook:

  • Future research should focus on implementing and evaluating ABI models in real-world settings.
  • ABI has the potential to significantly impact public health outcomes and economic value.
  • Continued exploration of collaborative frameworks is crucial for advancing medical progress.